Based upon this study, the Food and Drug Administration (FDA) has approved the assessment of PD-L1 by Ventana SP142-stained immunohistochemistry (IHC) in triple negative breast cancer for selecting patients to receive immunotherapy7. Here, CD274 is linked to triple-negative breast carcinoma.